Back

The effect of a selective urate reabsorption inhibitor dotinurad on uric acid and renal function in patients with hyperuricemia and hypertension.

30 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Therapeutic approaches to hypertension and its comorbidities Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Tatsuya Mizoguchi

Nagoya City University Graduate School of Medical Sciences, Nagoya (Japan)

3 More presentations in this session

Presentation thumbnail
Blood pressure lowering treatment for prevention of cardiovascular diseases in people with and without chronic kidney disease: an individual participant-level data meta-analysis
Ms G. Zeng (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
App-based multimodal lifestyle-intervention for essential hypertension: a randomized-controlled, decentralized trial in Germany
Professor F. Limbourg (Hannover, DE)
Abstract Slides Video
Presentation thumbnail
Impact of plateau on antihypertensive efficacy among hypertensive highlanders : a post hoc analysis of the OMAN Trial
Doctor X. Zuo (Sichuan, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Therapeutic approaches to hypertension and its comorbidities

The Event

Event poster

ESC Congress 2025

30 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Comparative clinical outcomes on renal function and mortality of uricosuric agents versus xanthine oxidase inhibitors in patients with hyperuricemia and cardiovascular risks
thumbnail
Congress Presentation
Sacubitril/Allisartan in hyperuricemia
thumbnail
Congress Presentation
Hypertension and urate

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources